Sancuso: transdermal patch formulation of nausea drug

ProStrakan has launched Sancuso (granisetron) transdermal patch for the treatment of chemotherapy-induced nausea and vomiting.

Patients should avoid exposing the patch application site to sunlight or direct heat during and for 10 days after removal.
Patients should avoid exposing the patch application site to sunlight or direct heat during and for 10 days after removal.

It is the first 5HT3 antagonist to be made available in this form.

Patients should apply a single Sancuso patch (releasing granisetron 3.1mg/24 hours) to the upper arm or abdomen 24 to 48 hours before chemotherapy. The patch should be removed a minimum of 24 hours after completion of the chemotherapy but can be worn continuously for up to 7 days.

Non-inferior to oral granisetron

In clinical trials, Sancuso was non-inferior to oral granisetron (2mg once daily) and was generally well tolerated. Constipation was the most commonly reported adverse effect. Mild application site reactions were reported, which did not lead to discontinuation of treatment. If a severe or generalised skin reaction occurs, the patch should be removed.

View Sancuso drug record

Further information: ProStrakan

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.